Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study] (LISA Pilot)

Livongo Health

Status

Terminated

Conditions

Type 2 Diabetes Treated With Insulin

Treatments

Device: Livongo-Insulia Study App

Study type

Interventional

Funder types

Industry

Identifiers

NCT03980236

CP04573.A

Details and patient eligibility

About

The Livongo-Insulia Study App Pilot Study (LISA Pilot) is a 3-month, prospective, interventional study. The purpose of this pilot study is to evaluate the feasibility of using the Livongo-Insulia Study App for individuals with type 2 diabetes using basal insulin. This will be assessed by measuring the impact of the Livongo-Insulia Study App on glycemic control for these individuals.

Enrollment

21 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 18 years
Lives in the U.S.
Able to speak, read and write in English
Diagnosed with type 2 diabetes
Currently treated with long-acting basal insulin analog (Lantus, Levemir, Toujeo, Basaglar, Tresiba U-100) and taking 1 injection per day
Takes a daily dose ≤ 0.75 units/kg
Estimated A1c ≥ 8% (based on existing Livongo data)
Has been enrolled in Livongo for at least 12 weeks
Uses an iPhone compatible with Insulia's compatibility matrix (iPhone 5 or higher; iOS 8 or newer)
Willing to complete study questionnaires
Willing to complete at-home A1c kits
Willing to check before breakfast blood glucose at least once per day

Exclusion criteria

Diagnosis of type 1 diabetes
Currently using a long-acting basal insulin analog that is not supported by Insulia
Currently using rapid-acting, short-acting, or intermediate-acting or premixed insulins
Currently pregnant or planning pregnancy